Cholera vaccines help in preventing the spread of cholera disease caused by Vibrio cholerae bacterium which can cause acute diarrhea and severe dehydration if not treated on time. The vaccines boost the body's immunity against the disease making it critical for travelers visiting endemic regions.

The Global Cholera Vaccines Market is estimated to be valued at US$ 82.5 MN in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Cholera Vaccines market are Sanofi, Biovac.co.za., EMERGENT, Celldex Therapeutics, Valneva SE, Hilleman Laboratories, Shanghai United Cell Biotechnology Co., Ltd (Hillhouse Capital), PaxVax, Inc., Astellas Pharma Inc., and EUBIOLOGICS CO., LTD. Sanofi's live oral vaccine named Dukoral is one of the most widely used cholera vaccine across the world.

The growing prevalence of Cholera Vaccines Market Size across Asia, Africa and South America is driving significant demand for cholera vaccines from governmental and non-governmental organizations. As per WHO estimates, every year there are over 1.3 to 4 million cases and 21,000 to 143,000 deaths due to cholera globally.

Market Trends

- Growing focus on developing affordable cholera vaccines: Given the requirement of frequent booster doses with some existing vaccines, efforts are ongoing to develop affordable single-dose oral vaccines that provide long lasting protection.

- Increasing demand for multivalent oral cholera vaccines: Given the recurrence of multiple diarrheal diseases, demand is growing for multivalent oral vaccines offering protection against cholera as well as other diarrhea-causing pathogens.

Market Opportunities

- Expanding vaccination programs: Global health organizations aim to expand the reach of cholera vaccination programs to endemic areas through coordinated efforts between countries. This presents significant revenue potential.

- Emerging markets: Emerging countries in Asia Pacific and Latin America with high disease prevalence offer lucrative opportunities for cholera vaccine manufacturers to increase regional market share.

Impact of COVID-19 on Global Cholera Vaccines Market

The COVID-19 pandemic negatively impacted the global cholera vaccines market. During the initial outbreak, focus shifted towards developing vaccines and therapeutics for Covid-19, diverting research funding away from other diseases. Several clinical trials had to be paused or delayed, slowing down product development timelines. Supply chain disruptions and lockdowns led to delays in production and distribution of existing cholera vaccines. This hindered timely availability and accessibility of these vaccines globally. Travel restrictions impacted transportation of vaccines to endemic regions. However, with increasing vaccination rates against Covid-19 globally, focus is returning towards cholera prevention. The pandemic has highlighted the importance of vaccination programmes. Moving forward, manufacturers are looking to enhance production capabilities and supply chain resilience to deal with future outbreaks in a timely manner. Strong collaboration between manufacturers, governments and global health agencies will also play a key role in effective pandemic preparedness and response.

In terms of growth rate, the Latin American region is expected to witness highest CAGR during the forecast period. This is attributed to increasing focus of governments and health organizations on cholera prevention and control through vaccination in countries like Haiti, Dominican Republic and Brazil where outbreaks are frequently reported. Large donations of oral vaccines through initiatives like the International Coordinating Group help increase accessibility in these resource-constrained settings, driving higher adoption.

Get more insights on Cholera Vaccines Market